Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock and renal disease in North America. More Details
High growth potential with mediocre balance sheet.
Share Price & News
How has Spectral Medical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: EDT is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: EDT's weekly volatility (7%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: EDT underperformed the Canadian Biotechs industry which returned -23% over the past year.
Return vs Market: EDT underperformed the Canadian Market which returned 36.9% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Spectral Medical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StSpectral Medical Inc.'s (TSE:EDT) Path To Profitability
2 months ago | Simply Wall StSpectral Medical (TSE:EDT) Is In A Good Position To Deliver On Growth Plans
3 months ago | Simply Wall StSpectral Medical's(TSE:EDT) Share Price Is Down 49% Over The Past Five Years.
Is Spectral Medical undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether Spectral Medical is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Spectral Medical has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
How is Spectral Medical forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EDT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.5%).
Earnings vs Market: EDT is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: EDT's is expected to become profitable in the next 3 years.
Revenue vs Market: EDT's revenue (59.4% per year) is forecast to grow faster than the Canadian market (6.8% per year).
High Growth Revenue: EDT's revenue (59.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if EDT's Return on Equity is forecast to be high in 3 years time
How has Spectral Medical performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EDT is currently unprofitable.
Growing Profit Margin: EDT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: EDT is unprofitable, but has reduced losses over the past 5 years at a rate of 12.3% per year.
Accelerating Growth: Unable to compare EDT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EDT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.6%).
Return on Equity
High ROE: EDT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is Spectral Medical's financial position?
Financial Position Analysis
Short Term Liabilities: EDT has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: EDT has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: EDT is debt free.
Reducing Debt: EDT's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EDT has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: EDT has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 38.3% each year
What is Spectral Medical current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate EDT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate EDT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EDT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EDT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of EDT's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Chris Seto has been the Chief Financial Officer of Spectral Medical Inc. since August 2, 2019 and also has been its Chief Operating Officer since June 4, 2020. He has been Chief Executive Officer of Sp...
CEO Compensation Analysis
Compensation vs Market: Chris's total compensation ($USD322.00K) is above average for companies of similar size in the Canadian market ($USD156.41K).
Compensation vs Earnings: Insufficient data to compare Chris's compensation with company performance.
Experienced Management: EDT's management team is considered experienced (4.1 years average tenure).
Experienced Board: EDT's board of directors are considered experienced (6.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.6%.
Spectral Medical Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Spectral Medical Inc.
- Ticker: EDT
- Exchange: TSX
- Founded: 1991
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$130.050m
- Shares outstanding: 250.10m
- Website: https://www.spectraldx.com
Number of Employees
- Spectral Medical Inc.
- 135 The West Mall
- Unit 2
- M9C 1C2
Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock and renal disease in North America. The company markets Endotoxin Activity Assay, a rapi...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/09 22:57|
|End of Day Share Price||2021/05/07 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.